Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Decreased by LSV Asset Management

LSV Asset Management lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,927,999 shares of the biopharmaceutical company’s stock after selling 210,210 shares during the quarter. Gilead Sciences accounts for 1.0% of LSV Asset Management’s portfolio, making the stock its 8th biggest holding. LSV Asset Management owned about 0.48% of Gilead Sciences worth $480,227,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Tompkins Financial Corp increased its position in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the period. OFI Invest Asset Management bought a new position in Gilead Sciences in the third quarter worth approximately $26,000. Fortitude Family Office LLC purchased a new position in Gilead Sciences during the 4th quarter worth $29,000. Rakuten Securities Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $33,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $40,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 0.8 %

NASDAQ:GILD traded down $0.55 during mid-day trading on Friday, hitting $64.78. 7,822,720 shares of the company’s stock traded hands, compared to its average volume of 7,345,331. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The company has a market capitalization of $80.66 billion, a P/E ratio of 179.94, a P/E/G ratio of 1.30 and a beta of 0.22. The company has a fifty day moving average of $70.55 and a 200 day moving average of $75.83. Gilead Sciences, Inc. has a twelve month low of $64.33 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.37 earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analyst Ratings Changes

Several brokerages have recently commented on GILD. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Mizuho cut their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Maxim Group lowered their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research note on Wednesday, April 24th. Finally, Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.